N43CA130014-004 (N43) | |||
---|---|---|---|
Title | A Novel Agent That Reduces Radiation Side Effects in Head and Neck Cancer Patient | ||
Institution | COLBY PHARMACEUTICAL COMPANY, MENLO PARK, CA | ||
Principal Investigator | ZARLING, DAVID | NCI Program Director | |
Cancer Activity | Division | ||
Funded Amount | $1,499,978 | Project Dates | 09/12/2013 - 07/31/2016 |
Fiscal Year | 2014 | Project Type | Contract |
Research Topics w/ Percent Relevance | Cancer Types w/ Percent Relevance | ||
Cancer (100.0%) Digestive Diseases (100.0%) |
Head and Neck (100.0%) | ||
Research Type | |||
Systemic Therapies - Discovery and Development | |||
Abstract | |||
No abstract available. |